Capital Bank & Trust’s Viridian Therapeutics VRDN Stock Holding History

Capital Bank & Trust’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-252	Closed	-$21K	–	846
2018 Q3	$21K	Hold	252	–	–	﹤0.01%	589
2018 Q2	$24K	Hold	252	–	–	﹤0.01%	476
2018 Q1	$27K	Hold	252	–	–	﹤0.01%	440
2017 Q4	$39K	Hold	252	–	–	﹤0.01%	441
2017 Q3	$35K	Buy	+252	New	+$42.4K	﹤0.01%	403

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Bank & Trust's VRDN Position: Q4 2018 in Review

Capital Bank & Trust sold out of Viridian Therapeutics (VRDN) in Q4 2018, closing a stake of 252 shares — an estimated $21K sold.

Capital Bank & Trust first reported a position in VRDN in Q3 2017 and held it in 5 quarters. The position peaked at $39K in Q4 2017. 56 funds tracked by Wall St. Rank hold VRDN as of Q4 2018.

Capital Bank & Trust reported no remaining Viridian Therapeutics position as of Q4 2018 after selling out during the quarter.
Capital Bank & Trust sold 252 Viridian Therapeutics shares in Q4 2018, an estimated $21K.
Capital Bank & Trust first reported a position in Viridian Therapeutics in Q3 2017 and held it in 5 quarters.
Capital Bank & Trust's Viridian Therapeutics position peaked at $39K in Q4 2017.
56 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2018.

Based on Capital Bank & Trust's 13F filing for Q4 2018, filed 14 Feb 2019.